DYAX, DEBIOPHARM REVISE DEVELOPMENT DEAL

Biotech company Dyax Corp. and Swiss drug maker Debiopharm SA said Tuesday they have restructured their development agreement for a drug to treat lung disorders. Financial details of the agreement were not disclosed. Under the new agreement, Debiopharm will get exclusive global rights for the development and commercialization of DX-890 for cystic fibrosis and acute respiratory distress syndrome, or ARDS.

MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20051220&ID=5370010)